Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2009. The report serves as a notification to the market regarding the Company's issued share capital and voting rights structure as of July 31, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's share capital composition as of July 31, 2009:
- Total issued Ordinary shares: 5,662,640,871 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,188,446,713.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,188,446,713) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the number of shares held in Treasury (474,194,158) to understand the float.
- Check subsequent filings for financial performance data, as this 6-K contains no operational or financial results.